| [ | |
| { | |
| "model_name":"abrocitinib 200 mg QD", | |
| "score":86.6, | |
| "EASI-50":86.6, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", | |
| "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", | |
| "notes":"Combination therapy RCTs" | |
| }, | |
| { | |
| "model_name":"Upadacitinib", | |
| "score":85.6, | |
| "EASI-50":null, | |
| "Time":"Week 12", | |
| "EASI percent reduction":"85.6%", | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan", | |
| "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.16549", | |
| "notes":"Median percent reduction in EASI at week 12 with Upadacitinib 15 mg\/day plus topical corticosteroids." | |
| }, | |
| { | |
| "model_name":"upadacitinib 30 mg once daily (QD)", | |
| "score":83.6, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":83.6, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", | |
| "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", | |
| "notes":"Monotherapy RCTs" | |
| }, | |
| { | |
| "model_name":"dupilumab 300 mg Q2W", | |
| "score":82.4, | |
| "EASI-50":82.4, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", | |
| "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", | |
| "notes":"Combination therapy RCTs" | |
| }, | |
| { | |
| "model_name":"abrocitinib 100 mg QD", | |
| "score":79.7, | |
| "EASI-50":79.7, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", | |
| "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", | |
| "notes":"Combination therapy RCTs" | |
| }, | |
| { | |
| "model_name":"Human", | |
| "score":79.2, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"79.2", | |
| "SITE [57]":"67.5", | |
| "MMSI [68]":"97.2", | |
| "OmniSpatial [23]":"92.63", | |
| "MindCube ∗ [69]":"94.55", | |
| "STARE [32]":"96.50", | |
| "CoreCognition [33]":"86.98", | |
| "SpatialViz [55]":"82.46", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"None" | |
| }, | |
| { | |
| "model_name":"abrocitinib 200 mg QD", | |
| "score":74.6, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":74.6, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", | |
| "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", | |
| "notes":"Monotherapy RCTs" | |
| }, | |
| { | |
| "model_name":"Upadacitinib", | |
| "score":73.6, | |
| "EASI-50":null, | |
| "Time":"Week 4", | |
| "EASI percent reduction":"73.6%", | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan", | |
| "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.16549", | |
| "notes":"Median percent reduction in EASI at week 4 with Upadacitinib 15 mg\/day plus topical corticosteroids." | |
| }, | |
| { | |
| "model_name":"upadacitinib 15 mg QD", | |
| "score":70.5, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":70.5, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", | |
| "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", | |
| "notes":"Monotherapy RCTs" | |
| }, | |
| { | |
| "model_name":"Upadacitinib", | |
| "score":67.7, | |
| "EASI-50":null, | |
| "Time":"Week 12", | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":"67.7%", | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan", | |
| "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.16549", | |
| "notes":"Achievement rate of EASI 75 at week 12 with Upadacitinib 15 mg\/day plus topical corticosteroids." | |
| }, | |
| { | |
| "model_name":"dupilumab 300 mg every 2 weeks (Q2W)", | |
| "score":63.4, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":63.4, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", | |
| "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", | |
| "notes":"Monotherapy RCTs" | |
| }, | |
| { | |
| "model_name":"Qwen3-8B-Instruct [65]", | |
| "score":57.9, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"57.90", | |
| "SITE [57]":"45.83", | |
| "MMSI [68]":"31.10", | |
| "OmniSpatial [23]":"45.73", | |
| "MindCube ∗ [69]":"29.42", | |
| "STARE [32]":"39.76", | |
| "CoreCognition [33]":"69.67", | |
| "SpatialViz [55]":"17.54 †", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"† indicates cases where generations were truncated due to overlong chains of thought, yielding no final answer; such instances are counted as incorrect, which depresses the score." | |
| }, | |
| { | |
| "model_name":"abrocitinib 100 mg QD", | |
| "score":56.7, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":56.7, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis", | |
| "source_url":"https:\/\/doi.org\/10.1111\/jdv.17351", | |
| "notes":"Monotherapy RCTs" | |
| }, | |
| { | |
| "model_name":"InternVL3.5-8B [56]", | |
| "score":56.05, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"56.05", | |
| "SITE [57]":"43.79", | |
| "MMSI [68]":"27.30", | |
| "OmniSpatial [23]":"46.71", | |
| "MindCube ∗ [69]":"42.50", | |
| "STARE [32]":"40.18", | |
| "CoreCognition [33]":"66.40", | |
| "SpatialViz [55]":"23.98", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"None" | |
| }, | |
| { | |
| "model_name":"GPT-5-2025-08-07 [45]", | |
| "score":55.03, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"55.03", | |
| "SITE [57]":"61.88", | |
| "MMSI [68]":"41.80", | |
| "OmniSpatial [23]":"59.90", | |
| "MindCube ∗ [69]":"56.30", | |
| "STARE [32]":"54.59", | |
| "CoreCognition [33]":"84.37", | |
| "SpatialViz [55]":"51.27", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"None" | |
| }, | |
| { | |
| "model_name":"Gemini-2.5-pro-2025-06 [52]", | |
| "score":53.57, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"53.57", | |
| "SITE [57]":"57.06", | |
| "MMSI [68]":"38.00", | |
| "OmniSpatial [23]":"55.38", | |
| "MindCube ∗ [69]":"57.60", | |
| "STARE [32]":"49.14", | |
| "CoreCognition [33]":"76.70", | |
| "SpatialViz [55]":"42.71", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"None" | |
| }, | |
| { | |
| "model_name":"Upadacitinib", | |
| "score":51.6, | |
| "EASI-50":null, | |
| "Time":"Week 4", | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":"51.6%", | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real‐world practice in Japan", | |
| "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.16549", | |
| "notes":"Achievement rate of EASI 75 at week 4 with Upadacitinib 15 mg\/day plus topical corticosteroids." | |
| }, | |
| { | |
| "model_name":"high dose hUCB-MSC", | |
| "score":50.0, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":50.0, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I\/IIa Studies", | |
| "source_url":"https:\/\/doi.org\/10.1002\/stem.2401", | |
| "notes":"Fifty-five percent of patients in high dose hUCB-MSC-treated group showed a 50% reduction in the EASI score." | |
| }, | |
| { | |
| "model_name":"EASI 50", | |
| "score":50.0, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":50.0, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study*", | |
| "source_url":"https:\/\/doi.org\/10.1111\/bjd.19457", | |
| "notes":"Meaningful percentage MIC regardless of baseline AD severity." | |
| }, | |
| { | |
| "model_name":"Seed-1.6-2025-06-15 [51]", | |
| "score":49.91, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"49.91", | |
| "SITE [57]":"54.61", | |
| "MMSI [68]":"38.30", | |
| "OmniSpatial [23]":"49.32", | |
| "MindCube ∗ [69]":"48.75", | |
| "STARE [32]":"46.06", | |
| "CoreCognition [33]":"77.17", | |
| "SpatialViz [55]":"34.58", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"None" | |
| }, | |
| { | |
| "model_name":"GPT-5-mini-2025-08-07 [45]", | |
| "score":48.67, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"48.67", | |
| "SITE [57]":"52.47", | |
| "MMSI [68]":"34.10", | |
| "OmniSpatial [23]":"55.52", | |
| "MindCube ∗ [69]":"56.69", | |
| "STARE [32]":"52.51", | |
| "CoreCognition [33]":"77.77", | |
| "SpatialViz [55]":"44.66", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"None" | |
| }, | |
| { | |
| "model_name":"Grok-4-2025-07-09 [62]", | |
| "score":47.92, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"47.92", | |
| "SITE [57]":"47.01", | |
| "MMSI [68]":"37.80", | |
| "OmniSpatial [23]":"46.84", | |
| "MindCube ∗ [69]":"63.56", | |
| "STARE [32]":"26.90", | |
| "CoreCognition [33]":"79.27", | |
| "SpatialViz [55]":"19.40 †", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"† indicates cases where generations were truncated due to overlong chains of thought, yielding no final answer; such instances are counted as incorrect, which depresses the score." | |
| }, | |
| { | |
| "model_name":"InternVL3-78B [79]", | |
| "score":47.55, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"47.55", | |
| "SITE [57]":"52.72", | |
| "MMSI [68]":"30.50", | |
| "OmniSpatial [23]":"50.95", | |
| "MindCube ∗ [69]":"49.52", | |
| "STARE [32]":"42.00", | |
| "CoreCognition [33]":"71.16", | |
| "SpatialViz [55]":"31.10", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"None" | |
| }, | |
| { | |
| "model_name":"GPT-5-nano-2025-08-07 [45]", | |
| "score":43.22, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"43.22", | |
| "SITE [57]":"35.81", | |
| "MMSI [68]":"28.90", | |
| "OmniSpatial [23]":"47.81", | |
| "MindCube ∗ [69]":"41.48", | |
| "STARE [32]":"46.05", | |
| "CoreCognition [33]":"67.92", | |
| "SpatialViz [55]":"35.59", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"None" | |
| }, | |
| { | |
| "model_name":"InternVL3-8B [79]", | |
| "score":42.14, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"42.14", | |
| "SITE [57]":"41.15", | |
| "MMSI [68]":"28.00", | |
| "OmniSpatial [23]":"46.25", | |
| "MindCube ∗ [69]":"41.54", | |
| "STARE [32]":"41.36", | |
| "CoreCognition [33]":"60.92", | |
| "SpatialViz [55]":"30.00", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"None" | |
| }, | |
| { | |
| "model_name":"Qwen2.5-VL-72B-Instruct [1]", | |
| "score":35.77, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"35.77", | |
| "SITE [57]":"47.41", | |
| "MMSI [68]":"32.50", | |
| "OmniSpatial [23]":"47.81", | |
| "MindCube ∗ [69]":"42.40", | |
| "STARE [32]":"38.37", | |
| "CoreCognition [33]":"69.22", | |
| "SpatialViz [55]":"32.54", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"None" | |
| }, | |
| { | |
| "model_name":"Random Choice", | |
| "score":34.0, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"34.00", | |
| "SITE [57]":"0.0", | |
| "MMSI [68]":"25.00", | |
| "OmniSpatial [23]":"24.98", | |
| "MindCube ∗ [69]":"32.35", | |
| "STARE [32]":"34.80", | |
| "CoreCognition [33]":"33.93", | |
| "SpatialViz [55]":"25.08", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"VSI random choice here is chance level(Frequency)." | |
| }, | |
| { | |
| "model_name":"Qwen2.5-VL-7B-Instruct [1]", | |
| "score":32.3, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"32.30", | |
| "SITE [57]":"37.64", | |
| "MMSI [68]":"26.80", | |
| "OmniSpatial [23]":"39.07", | |
| "MindCube ∗ [69]":"36.05", | |
| "STARE [32]":"35.03", | |
| "CoreCognition [33]":"62.16", | |
| "SpatialViz [55]":"26.78", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"None" | |
| }, | |
| { | |
| "model_name":"Easi-CRISPR", | |
| "score":30.0, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":"30–60%", | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"Easi-CRISPR for creating knock-in and conditional knockout mouse models using long ssDNA donors", | |
| "source_url":"https:\/\/doi.org\/10.1038\/nprot.2017.153", | |
| "notes":"Typically 30-60% efficiency, reaching as high as 100% in some cases." | |
| }, | |
| { | |
| "model_name":"Qwen2.5-VL-3B-Instruct [1]", | |
| "score":27.0, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":"27.00", | |
| "SITE [57]":"33.14", | |
| "MMSI [68]":"28.60", | |
| "OmniSpatial [23]":"42.47", | |
| "MindCube ∗ [69]":"37.60", | |
| "STARE [32]":"37.83", | |
| "CoreCognition [33]":"60.19", | |
| "SpatialViz [55]":"21.86", | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":null, | |
| "source_title":"EASI", | |
| "source_url":"https:\/\/arxiv.org\/pdf\/2508.13142.pdf", | |
| "notes":"None" | |
| }, | |
| { | |
| "model_name":"EASI", | |
| "score":0.47, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":0.75, | |
| "median EASI":null, | |
| "source_title":"Development and Validation of a Tool to Improve Physician Identification of Elder Abuse: The Elder Abuse Suspicion Index (EASI)©", | |
| "source_url":"https:\/\/doi.org\/10.1080\/08946560801973168", | |
| "notes":"The EASI had an estimated sensitivity and specificity of 0.47 and 0.75" | |
| }, | |
| { | |
| "model_name":"placebo", | |
| "score":-1.3, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":-1.3, | |
| "source_title":"Phase 2a, randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study of a H<sub>4<\/sub>R‐antagonist (<scp>JNJ<\/scp>‐39758979) in<scp>J<\/scp>apanese adults with moderate atopic dermatitis", | |
| "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.12726", | |
| "notes":"at week 6" | |
| }, | |
| { | |
| "model_name":"JNJ-39758979 300 mg", | |
| "score":-3.0, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":-3.0, | |
| "source_title":"Phase 2a, randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study of a H<sub>4<\/sub>R‐antagonist (<scp>JNJ<\/scp>‐39758979) in<scp>J<\/scp>apanese adults with moderate atopic dermatitis", | |
| "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.12726", | |
| "notes":"at week 6" | |
| }, | |
| { | |
| "model_name":"JNJ-39758979 100 mg", | |
| "score":-3.7, | |
| "EASI-50":null, | |
| "Time":null, | |
| "EASI percent reduction":null, | |
| "EASI-50 response":null, | |
| "VSI [66]":null, | |
| "SITE [57]":null, | |
| "MMSI [68]":null, | |
| "OmniSpatial [23]":null, | |
| "MindCube ∗ [69]":null, | |
| "STARE [32]":null, | |
| "CoreCognition [33]":null, | |
| "SpatialViz [55]":null, | |
| "EASI 75 achievement rate":null, | |
| "EASI score reduction (%)":null, | |
| "percentage MIC":null, | |
| "efficiency":null, | |
| "specificity":null, | |
| "median EASI":-3.7, | |
| "source_title":"Phase 2a, randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study of a H<sub>4<\/sub>R‐antagonist (<scp>JNJ<\/scp>‐39758979) in<scp>J<\/scp>apanese adults with moderate atopic dermatitis", | |
| "source_url":"https:\/\/doi.org\/10.1111\/1346-8138.12726", | |
| "notes":"at week 6" | |
| } | |
| ] |